Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Mengjie Chen, Jianxin Tu, Mingyu Huang, Yongjun Cheng, Li Sun
OBJECTIVES: Systemic lupus erythematosus (SLE) and the Epstein-Barr virus (EBV) are very closely related. This study estimated the impact of EBV infection status on clinical manifestations and disease remission in patients with SLE. METHOD: A retrospective study was performed using electronic health records of patients with SLE. The SLE disease activity index (SLEDAI-2 K) was used to assess disease activity. VCAIgM or EAIgM positive or EBVDNA copies ≥ 50 IU/mL were defined as lytic infection group, EBNA-IgG or VCAIgG-positive and who were negative for both VCAIgM and EAIgM with EBVDNA copies < 50 IU/mL were defined as the latent infection group...
March 20, 2024: Clinical Rheumatology
#22
JOURNAL ARTICLE
Violeta Rabrenović, Milica Petrović, Milorad Rabrenović, Dejan Pilčević, Nemanja Rančić
BACKGROUND: Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE). There are increased studies examining the role of different markers that would facilitate diagnosis, LN activity monitoring, relapse occurrence, and the right time to introduce maintenance therapy. We aimed to examine the importance of determining the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), systemic immuneinflammatory index (SII) and systemic inflammatory response index (SIRI) in LN, comparing their significance with other standard parameters of active disease...
January 25, 2024: Journal of Medical Biochemistry
#23
JOURNAL ARTICLE
Irene Altabás-González, José María Pego-Reigosa, Coral Mouriño, Norman Jiménez, Andrea Hernández-Martín, Ivette Casafont-Solé, Judit Font Urguelles, José Andrés Román-Ivorra, Marta de la Rubia Navarro, María Galindo-Izquierdo, Tarek Carlos Salman-Monte, Javier Narváez, Paola Vidal-Montal, María Jesús García-Villanueva, Sandra Garrote-Corral, María Ángeles Blázquez-Cañamero, Carlos Marras, María Piqueras-García, Julia Martínez-Barrio, Marina Sánchez-Lucas, Josefina Cortés-Hernández, Eleonora Penzo, Jaime Calvo, Juan Ramón de Dios, Belén Álvarez Rodríguez, Margarida Vasques-Rocha, Eva Tomero, Raúl Menor-Almagro, Myriam Gandía, José A Gómez-Puerta, Beatriz Frade-Sosa, Consuelo Ramos-Giráldez, Carmen Trapero-Pérez, Elvira Diez, Clara Moriano, Alejandro Muñoz-Jiménez, Iñigo Rúa-Figueroa
OBJECTIVES: To provide an overview on the current use of belimumab (BLM) in SLE patients in clinical practice and to examine its efficacy in terms of standardized outcomes, drug survival, as well as patient and safety profiles. METHODS: A longitudinal retrospective multicentre cohort including SLE patients treated with BLM at 18 Spanish centers. Data was collected upon initiation of BLM, at 6 and 12 months after initiation, and at the last recorded visit...
March 15, 2024: Rheumatology
#24
JOURNAL ARTICLE
Siwan Huang, Yinghua Chen, Yanan Song, Kaiyuan Wu, Tiange Chen, Yuan Zhang, Wenxiao Jia, Hai-Tao Zhang, Dan-Dan Liang, Jing Yang, Cai-Hong Zeng, Xiang Li, Zhi-Hong Liu
OBJECTIVES: To develop an interpretable deep learning model of lupus nephritis (LN) relapse prediction based on dynamic multivariable time-series data. DESIGN: A single-centre, retrospective cohort study in China. SETTING: A Chinese central tertiary hospital. PARTICIPANTS: The cohort study consisted of 1694 LN patients who had been registered in the Nanjing Glomerulonephritis Registry at the National Clinical Research Center of Kidney Diseases, Jinling Hospital from January 1985 to December 2010...
March 14, 2024: BMJ Open
#25
REVIEW
Chung-Jen Chen
SLE affects females rather than males with a ratio of about 9:1. Owing to the high morbidity with multiple organ involvement, SLE flare-up remains a challenge for women's health. In an accumulation of the past 70 years of studies globally, EBV has been found to be strongly associated with SLE. In the past two decades, EBV reactivation has been proven as prevalent in SLE patients as well as being strongly associated with higher SLE activity and higher prevalence of SLE flare. Hence, strategies to control EBV reactivation in SLE including pharmacological (such as Tenofovir prodrugs TDF and TAF) and non-pharmacological approaches are being developed...
March 2024: Taiwanese Journal of Obstetrics & Gynecology
#26
REVIEW
Alexandre Teboul, Laurent Arnaud, François Chasset
Antimalarials (AMs), particularly hydroxychloroquine (HCQ) and chloroquine (CQ), are the cornerstone of the treatment for both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). HCQ and CQ are recommended as first-line oral agents in all CLE guidelines. Initially thought to have potential therapeutic effects against COVID-19, HCQ has drawn significant attention in recent years, highlighting concerns over its potential toxicity among patients and physicians. This review aims to consolidate current evidence on the efficacy of AMs in CLE...
March 14, 2024: Journal of Dermatology
#27
REVIEW
Divya Katikaneni, Laurence Morel, Yogesh Scindia
Lupus nephritis (LN) is the most severe end-organ pathology in Systemic Lupus Erythematosus (SLE). Research has enhanced our understanding of immune effectors and inflammatory pathways in LN. However, even with the best available therapy, the rate of complete remission for proliferative LN remains below 50%. A deeper understanding of the resistance or susceptibility of renal cells to injury during the progression of SLE is critical for identifying new targets and developing effective long-term therapies. The complex and heterogeneous nature of LN, combined with the limitations of clinical research, make it challenging to investigate the aetiology of this disease directly in patients...
December 2024: Autoimmunity
#28
MULTICENTER STUDY
Jun Li, Liying Peng, Lijun Wu, Yufang Ding, Xinwang Duan, Jian Xu, Wei Wei, Zhen Chen, Cheng Zhao, Min Yang, Nan Jiang, Shangzhu Zhang, Qian Wang, Xinping Tian, Mengtao Li, Xiaofeng Zeng, Yan Zhao, Jiuliang Zhao
BACKGROUND: To investigate the role of antiphospholipid antibodies (aPLs) in the disease severity and prognosis of SLE-related thrombocytopenia (SLE-TP). METHODS: This multicenter prospective study was conducted based on data from the CSTAR registry. TP was defined as a platelet count<100 × 109 /L. Demographic characteristics, platelet count, clinical manifestations, disease activity, and autoantibody profiles were collected at baseline. Relapse was defined as the loss of remission...
March 12, 2024: Arthritis Research & Therapy
#29
JOURNAL ARTICLE
Hiroshi Oiwa, Takeshi Suga, Yohei Hosokawa, Kei Araki
OBJECTIVES: In addition to various immunosuppressive agents, belimumab and anifrolumab became available in Japan. We aimed to investigate glucocorticoid-free clinical remission in a single-centre retrospective cohort in October 2023. METHODS: Our cohort included patients with SLE who needed to start or increase glucocorticoids for disease activity and were followed up for more than 1 year. We investigated the rate of achievement of clinical remission off corticosteroids (CR off C), defined as no clinical score on the SLEDAI-2K without glucocorticoids, baseline predictors of CR off C, medications used when CR off C was achieved, and flare rates following CR off C...
March 12, 2024: Lupus
#30
JOURNAL ARTICLE
Elisabeth Cohen, Coralie Lheure, Saskia Ingen-Housz-Oro, Claire Hotz, Thomas Bettuzzi, Francois Chasset, Vincent Descamps, Lydia Deschamps, Matthieu Mahevas, Benjamin Terrier, Pierre Sohier, Sarah Guegan, Nora Kramkimel, Delphine Darbord, Johan Chanal, Benedicte Oulès, Selim Aractingi, Vannina Seta, Nicolas Dupin
Sarcoidosis is a systemic disease that affects the skin in about 25% of patients. The treatment of cutaneous sarcoidosis is guided by the extent of lesions, associated symptoms and organ involvement. To evaluate rates of response to various potential first-line treatments for cutaneous sarcoidosis during the year following treatment initiation. This retrospective multicentre study included 120 patients with cutaneous sarcoidosis. Treatment response was assessed retrospectively from the patients' medical records...
December 1, 2023: European Journal of Dermatology: EJD
#31
JOURNAL ARTICLE
Mohsen Soori, Seyed Hadi Mirhashemi, Fariborz Rashnoo, Gholamhosein Faghih, Fatemeh Ebrahimi, Amir Zamani, Azadeh Hakakzadeh
BACKGROUND: Obesity is one the most prevalent diseases all around the world. Some studies have shown a relationship between obesity and the worsening of rheumatic disorders. Higher rates of surgical complications might also be seen among these patients. METHODS: This retrospective-descriptive study was performed on 25 patients with rheumatic disease referred to Loghman Hakim Hospital (Tehran- Iran) and candidates for bariatric surgery (laparoscopic Roux-en-Y gastric and laparoscopic sleeve gastrectomy) from 2018 to 2020...
2024: Caspian Journal of Internal Medicine
#32
JOURNAL ARTICLE
Takehiro Nakai, Nanase Honda, Eri Soga, Sho Fukui, Ayako Kitada, Naoto Yokogawa, Masato Okada
BACKGROUND: Remission is a key treatment target in systemic lupus erythematosus (SLE) management. Given the direct correlation between lupus flares and elevated risks of adverse pregnancy outcomes (APOs), securing remission before conception becomes crucial. However, the association between clinical remission with active serology, and the risk of APOs is not thoroughly understood. Additionally, determining the optimal glucocorticoid dosage during pregnancy to mitigate APO risks remains under-researched...
March 9, 2024: Arthritis Research & Therapy
#33
REVIEW
Savino Sciascia, Silvia Grazietta Foddai, Marta Arbrile, Massimo Radin, Irene Cecchi, Alice Barinotti, Roberta Fenoglio, Dario Roccatello
Prompt disease control of flares in patients with systemic lupus erythematosus (SLE) is a priority in treatment strategy planning. However, the long-term dosage-related collateral effects of glucocorticoids (GCs) have pushed researchers towards the identification and utilization of novel biological agents that could both induce and maintain low disease activity and remission, especially in the context of lupus nephritis (LN). This scoping review aims at assessing the current evidence of the potential steroid-sparing effect of biologic therapies by reviewing phase II and phase III randomized, placebo-controlled trials involving SLE/LN patients...
March 9, 2024: Immunologic Research
#34
JOURNAL ARTICLE
Gaoning Wang, Liu Jing, Ying Wang, Arshad Mehmood, Huining Zhang, Ruoyi Guo, Lu Zhang, Bin Li
Interferon regulatory factor 5 (IRF5) is a critical transcription factor in the toll-like receptor signaling pathway. It is associated with autoimmune disorders, such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease. However, the relationship between the functional single nucleotide polymorphisms (SNPs) of IRF5 and its mRNA expression level in patients with neuromyelitis optica spectrum disorder remains unclear. The present study aimed to investigate the relationship between polymorphisms and mRNA expression levels of the IRF5 gene with the incidence of neuromyelitis optica spectrum disorder (NMOSD) in northern Chinese Han people...
March 7, 2024: Molecular Neurobiology
#35
JOURNAL ARTICLE
Vanessa P de Andrade, Alexandre M Dos Santos, Luciana P C Seguro, Emily F N Yuki, Michelle R U Lopes, Marcus V Grecco, Eduardo F Borba, Julia M A Greve, Samuel K Shinjo
OBJECTIVES: Transcranial direct current stimulation (tDCS) combined with aerobic exercise (tDCS-AE) effectively reduces fatigue in patients with fibromyalgia. However, no study has assessed this method in systemic lupus erythematosus (SLE) patients with significant fatigue. Therefore, we evaluated the safety and efficacy of tDCS-AE for significant fatigue symptoms in adult female SLE patients. METHODS: This randomised, sham-controlled, double-blind study included 25 patients with SLE in remission or low disease activity (SLEDAI-2K £4) and with significant fatigue [≥36 points on the Fatigue Severity Scale (FSS) or ≥38 points on the Modified Fatigue Scale (MFIS)]...
March 7, 2024: Clinical and Experimental Rheumatology
#36
JOURNAL ARTICLE
Beatriz Frade-Sosa, Tarek Carlos Salman-Monte, Javier Narváez, Irene Peralta, Sebastian Sandoval, Berta Magallares, Sergi Heredia, Nuria Sapena, Anne Riveros-Frutos, Alejandro Olivé, Hector Corominas, Josefina Cortés-Hernández, José A Gómez-Puerta
BACKGROUND: In 2017, belimumab (BEL) was approved in subcutaneous (SQ) administration. The effectiveness after switching from intravenous (IV) to SQ and patient satisfaction in daily clinical practice has not been studied. During the pandemic, patient follow-up and treatment were significantly affected, and some patients need a change from IV to SQ. Our aim was to evaluate daily clinical practice satisfaction to SQ BEL therapy in patients previously treated IV BEL. We hypothesized that SQ BEL in SLE patients previously treated with IV BEL was similar in effectiveness and conferred higher satisfaction...
March 6, 2024: Lupus
#37
JOURNAL ARTICLE
Yu Deng, Jennifer A Pacheco, Anika Ghosh, Anh Chung, Chengsheng Mao, Joshua C Smith, Juan Zhao, Wei-Qi Wei, April Barnado, Chad Dorn, Chunhua Weng, Cong Liu, Adam Cordon, Jingzhi Yu, Yacob Tedla, Abel Kho, Rosalind Ramsey-Goldman, Theresa Walunas, Yuan Luo
BACKGROUND: Systemic lupus erythematosus (SLE) is a rare autoimmune disorder characterized by an unpredictable course of flares and remission with diverse manifestations. Lupus nephritis, one of the major disease manifestations of SLE for organ damage and mortality, is a key component of lupus classification criteria. Accurately identifying lupus nephritis in electronic health records (EHRs) would therefore benefit large cohort observational studies and clinical trials where characterization of the patient population is critical for recruitment, study design, and analysis...
March 3, 2024: BMC Medical Informatics and Decision Making
#38
JOURNAL ARTICLE
Lisa Wu, Florian Kälble, Hanns-Martin Lorenz, Martin Zeier, Matthias Schaier, Andrea Steinborn
Systemic lupus erythematosus (SLE) is a sex biased chronic autoimmune disease affecting predominantly females during reproductive ages. Changes in the ratio of inducible costimulatory molecule (ICOS)+ regulatory (Treg) and non-regulatory responder (Tresp) CD4+ T cells proved to be crucial for the occurrence of high disease activity. Here, we investigated how the differentiation of ICOS+ CD45RA+ CD31+ recent thymic emigrant (RTE) Tresps into CD45RA- CD31- memory Tresps affects the percentages of ICOS+ Tresps within total CD4+ T cells...
March 1, 2024: Clinical and Experimental Medicine
#39
JOURNAL ARTICLE
Nail involvement in connective tissue diseases: an epidemiological, clinical, and dermoscopic study.
Azza Ghannem, Anissa Zaouak, Zohra Aydi, Mehdi Somai, Houda Hammami, Fatma Boussema, Samy Fenniche
BACKGROUND: The assessment of nail changes in connective tissue diseases (CTD) has been rarely explored in previous studies. The use of dermoscopy to study vascular changes in nailfolds is an interesting diagnostic technique. The aim of the study was to describe the epidemiological, clinical, and dermoscopic features of nail lesions in CTD. METHODS: A prospective study was performed at the Dermatology Department of Habib Thameur Hospital (Tunis, Tunisia) in collaboration with the Internal Medicine Department over a period of 15 months, from July 2020 to September 2021, including patients diagnosed with systemic sclerosis (SS), systemic lupus erythematosus (SLE) and dermatomyositis (DM)...
March 1, 2024: International Journal of Dermatology
#40
JOURNAL ARTICLE
Jingjing Wang, Wenyuan Lou, Mengyue Zhu, Yuanmao Tu, Duqun Chen, Dandan Qiu, Feng Xu, Dandan Liang, Zhen Cheng, Haitao Zhang
BACKGROUND: Lupus nephritis (LN) is a common disease with diverse clinical and pathological manifestations. A major challenge in the management of LN is the inability to predict its treatment response at an early stage. The objective of this study was to determine whether the density of tubulointerstitial macrophage infiltration can be used to predict treatment response in LN and whether its addition to clinicopathological data at the time of biopsy would improve risk prediction. METHODS: In this retrospective cohort study, 430 patients with LN in our hospital from January 2010 to December 2017 were included...
2024: Frontiers in Immunology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
